Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide D vs Oral semaglutide in Japanese Participants With Type 2 Diabetes
NCT07271251Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in glycated haemoglobin at 20 weeks. Started Dec 2025; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07271251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07271251.